ArticleNPJ precision oncology2023

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes.

Koh Furugaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.